FGF2 and prostate carcinoma: On the other hand, DPP-4 may inhibit the malignant phenotype of prostate cancer cells via the blockade of the signaling pathway of basic fibroblast growth factor [29] and the serum activity of DPP-4 is reduced in patients with metastatic prostate cancer [30].